# Peter J Houghton

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 39 papers | 3,702 citations | 236833 25 h-index | 302012 39 g-index |
| 40 all docs | 40 docs citations | 40 times ranked | 6076 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin. Science, 1997, 277, 99-101. | 6.0 | 896 |
| 2 | The pediatric preclinical testing program: Description of models and early testing results. Pediatric Blood and Cancer, 2007, 49, 928-940. | 0.8 | 430 |
| 3 | Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemotherapy and Pharmacology, 1995, 36, 393-403. | 1.1 | 331 |
| 4 | Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro. Cancer Research, 2004, 64, 2333-2337. | 0.4 | 312 |
| 5 | Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemotherapy and Pharmacology, 1992, 31, 229-239. | 1.1 | 208 |
| 6 | Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes and Cancer, 1989, 1, 23-35. | 1.5 | 205 |
| 7 | Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 799-805. | 0.8 | 162 |
| 8 | p53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Medical and Pediatric Oncology, 2000, 35, 96-103. | 1.0 | 112 |
| 9 | Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 37-45. | 0.8 | 112 |
| 10 | Initial testing of a monoclonal antibody (IMCâ€A12) against IGFâ€1R by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 54, 921-926. | 0.8 | 89 |
| 11 | Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemotherapy and Pharmacology, 1994, 34, 171-174. | 1.1 | 78 |
| 12 | Topotecan treatment of adults with primary malignant glioma. Cancer, 1999, 85, 1160-1165. | 2.0 | 65 |
| 13 | Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemotherapy and Pharmacology, 1999, 43, 454-460. | 1.1 | 62 |
| 14 | On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice. Cancer, 1980, 45, 1159-1167. | 2.0 | 56 |
| 15 | Clinical use of topoisomerase I inhibitors in anticancer treatment. Medical and Pediatric Oncology, 2000, 35, 385-402. | 1.0 | 48 |
| 16 | Resistance to rapamycin: a novel anticancer drug. Cancer and Metastasis Reviews, 2001, 20, 69-78. | 2.7 | 46 |
| 17 | Topoisomerase I interactive drugs in children with cancer. Investigational New Drugs, 1996, 14, 37-47. | 1.2 | 42 |
| 18 | Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemotherapy and Pharmacology, 1997, 40, 259-265. | 1.1 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemotherapy and Pharmacology, 1999, 43, 269-276. | 1.1 | 42 |
| 20 | Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemotherapy and Pharmacology, 1994, 33, 265-272. | 1.1 | 33 |
| 21 | Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemotherapy and Pharmacology, 2000, 45, 345-349. | 1.1 | 31 |
| 22 | Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemotherapy and Pharmacology, 1995, 36, 393-403. | 1.1 | 31 |
| 23 | Antitumor diarylsulfonylureas: novel agents with unfulfilled promise. Investigational New Drugs, 1996, 14, 271-280. | 1.2 | 30 |
| 24 | Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice. Cancer Chemotherapy and Pharmacology, 2001, 47, 211-221. | 1.1 | 29 |
| 25 | Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease. Oncotarget, 2020, 11, 510-522. | 0.8 | 26 |
| 26 | Age-associated genes in human mammary gland drive human breast cancer progression. Breast Cancer Research, 2020, 22, 64. | 2.2 | 20 |
| 27 | Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemotherapy and Pharmacology, 1992, 30, 423-432. | 1.1 | 19 |
| 28 | Analysis of phenoxazine chemosensitizers: An electron ionization and keV-ion beam bombardment mass spectrometry study. Biological Mass Spectrometry, 1994, 23, 140-146. | 0.5 | 14 |
| 29 | Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors. Cancer Chemotherapy and Pharmacology, 1995, 36, 45-52. | 1.1 | 14 |
| 30 | Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemotherapy and Pharmacology, 2001, 48, 413-416. | 1.1 | 14 |
| 31 | Clinical Trials Using Irinotecan. The American Journal of Pediatric Hematology/oncology, 2002, 24, 84-85. | 1.3 | 11 |
| 32 | The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft models. Cancer Chemotherapy and Pharmacology, 2000, 45, 21-30. | 1.1 | 10 |
| 33 | Single-cell RNA profiling identifies diverse cellular responses to EWSR1/FLI1 downregulation in Ewing sarcoma cells. Cellular Oncology (Dordrecht), 2022, 45, 19-40. | 2.1 | 10 |
| 34 | Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 1224-1226. | 0.8 | 9 |
| 35 | Evaluation of 3-(p-fluorophenyl)-l-alanyl-3-[m-bis(2-chloroethyl)aminophenyl]-l-alanyl-l-methionine ethyl ester HCl (PTT.119) against xenografts of human rhabdomyosarcoma. Cancer Chemotherapy and Pharmacology, 1988, 22, 201-204. | 1.1 | 4 |
| 36 | Kinetics of cellular permeability of phenoxazine and its dependence on P-glycoprotein expression. FEBS Letters, 1993, 322, 1-5. | 1.3 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models. Clinical Cancer Research, 2022, 28, 3836-3849. | 3.2 | 2 |
| 38 | Influence of guanine nucleotides on vincristine binding in tumor cytosols and purified tubulin: Evidence for an inhibitor of vincristine binding. Journal of Cellular Physiology, 1990, 144, 376-382. | 2.0 | 1 |
| 39 | p53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. , 2000, 35, 96. | | 1 |